657424-72-1

Upstream product

• 52046-55-6 2,N-dihydroxy-propionamidine 
• 618-46-2 m-Chlorobenzoyl chloride 
• 917-64-6 methyl magnesium iodide 
• 657424-70-9 5-(3-chloro-phenyl)-[1,2,4]oxadiazole-3-carbaldehyde 
• 52046-55-6 N',2-dihydroxypropanimidamide 

Downstream Products

• 660417-40-3 3-(1-bromo-ethyl)-5-(3-chloro-phenyl)-[1,2,4]oxadiazole 
• 657424-74-3 methanesulfonic acid 1-[5-(3-chloro-phenyl)-[1,2,4]oxadiazol-3-yl]-ethyl ester 
• 863307-52-2 3-(1-chloro-ethyl)-5-(3-chloro-phenyl)-[1,2,4]oxadiazole 
• 870974-12-2 4-(5-{1-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine 
• 870973-88-9 (1R)-1-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]ethyl acetate 

Relevant academic research and scientific papers

Substituted piperazines as metabotropic glutamate receptor antagonists

The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar1, Ar2, Hy, L, R1, m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses thereof, processes for making the compounds, as well as methods for the medical treatment of mGluR5-mediated disorders.

MGluR5 modulators V

The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS

The present invention is directed to compounds of formula (I): Wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, R1, R2, Rs

NEW COMPOUNDS

The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4, R, R1, R2, R3, R4, R5, R6, R7, m, n, o, p and q are defined as in any one of claims 1 to 12, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

NEW COMPOUNDS

The present invention relates to new compounds of formula I, (I) a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.